WEBULL
WebtradeDownload

ChemoMetec (CPSE:CHEMM) Lifts Revenue Guidance, Is The 8% Undervalued View Still Convincing?

Simply Wall St · 2d ago

ChemoMetec (CPSE:CHEMM) is back in focus after management raised revenue guidance for the 2026/27 financial year to DKK 560–590 million, compared with an earlier range of DKK 545–575 million.

The guidance lift arrives after a sharp rebound in ChemoMetec’s share price, with a 1-day share price return of 6.27% and a 90-day share price return of 44.44%. However, the year-to-date share price return is still down 13.27% and the 1-year total shareholder return has fallen 13.28%, while the 3-year total shareholder return of 87.97% points to much stronger longer term momentum.

Compare ChemoMetec’s guidance-led rebound with other lab and healthcare equipment players by scanning our hand picked 127 healthcare AI stocks that are also responding to fresh earnings outlooks.

ChemoMetec’s outlook is a touch brighter and the share price has already sprinted ahead. After this guidance tweak and buyback activity, does the balance of risk and potential reward still lean in favour of new buyers?

Most Popular Narrative: 8% Undervalued

ChemoMetec’s most followed narrative pegs fair value at DKK 638, which sits above the last close of DKK 585. That gap is what many investors are trying to explain.

Discontinuation of the NC-200 platform, combined with last time buys and customer validation of NC-203 and XM30 or XM40, creates a multiyear replacement cycle that can influence instrument revenue and support utilization driven earnings.

See why 1 investors see ChemoMetec as 8% undervalued.

Result: Fair Value of DKK638 (UNDERVALUED)

Still, the ChemoMetec narrative can crack if heavy R&D and automation spending fails to gain traction, or if NC-200 replacements disappoint on consumables usage.

Find out about the key risks to this ChemoMetec narrative.

Another View: ChemoMetec Through The P/E Lens

ChemoMetec might look appealing against a DKK638 fair value narrative, yet the current P/E of 49.9x tells a sharper story. That multiple sits above both the peer average of 29.9x and an estimated fair ratio of 20x, which points to clear valuation risk if expectations cool.

For a closer look at how this price stacks up against earnings power, sense check the full valuation breakdown with the See what the numbers say about this price — find out in our valuation breakdown..

CPSE:CHEMM P/E Ratio as at Oct 2026
CPSE:CHEMM P/E Ratio as at Oct 2026

Next Steps

Curious whether the current optimism around ChemoMetec really holds up under the hood? Take a moment now to weigh both sides of the story with the 2 key rewards and 2 important warning signs.

Looking for more ChemoMetec sized opportunities?

If ChemoMetec has your attention, do not stop here. Broader ideas can sharpen your watchlist and keep you closer to the next potential opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.